A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy Subjects and Patients (PBC/PSC)
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs PVT 201 (Primary)
- Indications Autoimmune hepatitis; Liver transplant rejection; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
- Focus Adverse reactions; First in man
- Sponsors Parvus Therapeutics
- 04 Feb 2025 New trial record